Live Breaking News & Updates on Revision Hip System

·
Full Year revenue $4,560 million, down -11.2% reported and -12.1% underlying
·
Trading profit margin 15.0% reflected
lower gross margins, negative leverage from SG&A costs and increased R&D investment
·
Operating profit margin of 6.5% included
restructuring costs related to efficiency programmes
·
Cash generated from operations $972 million (2019: $1,370 million), trading cash flow $690 million (2019: $970 million),
trading profit to cash conversion ratio 101% (2019: 83%)
·
Increased R&D investment, with recent product launches performing well
·
Delivered acquisitions in extremities, ENT and ASC segments, securing new innovation to support sustainable growth
·
Full Year 2020 dividend distribution of 37.5¢ per share, unchanged from 2019, reflecting confidence in
the business and strength ....

United States , New Zealand , Charles Reynolds , Roland Diggelmann , Susan Gilchrist Ayesha Bharmal , Asia Pacific , Andrew Swift , Nephew Fourth Quarter , Full Year , Chip Implant , Sports Medicine Joint Repair , Advanced Wound Management , Chief Executive Officer , Condensed Consolidated Financial , Nephew Fourth Quarter Trading , Fourth Quarter , Established Markets , Latin American , Orthopaedic Reconstruction , Sports Medicine , Advanced Wound Care , Advanced Wound Bioactives , Knee Implants , Chip Implants , Revision Hip System , Dual Mobility Hip System ,